Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Endoplasmic reticulum lumen |
Domain |
PF01532 Glycosyl hydrolase family 47 |
Function |
Initiates the endoplasmic reticulum-associated degradation (ERAD) that targets misfolded glycoproteins for degradation in an N-glycan-dependent manner. Catalyzes the first mannose trimming step, from Man9GlcNAc2 to Man8GlcNAc2 (PubMed:25092655). Extracts misfolded glycoproteins, but not glycoproteins undergoing productive folding, from the calnexin cycle. |
Biological Process |
GO:0006486 protein glycosylation GO:0006487 protein N-linked glycosylation GO:0006491 N-glycan processing GO:0006516 glycoprotein catabolic process GO:0006517 protein deglycosylation GO:0006986 response to unfolded protein GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0009311 oligosaccharide metabolic process GO:0009894 regulation of catabolic process GO:0009896 positive regulation of catabolic process GO:0010498 proteasomal protein catabolic process GO:0030433 ER-associated ubiquitin-dependent protein catabolic process GO:0030968 endoplasmic reticulum unfolded protein response GO:0030970 retrograde protein transport, ER to cytosol GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032527 protein exit from endoplasmic reticulum GO:0033157 regulation of intracellular protein transport GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0035977 protein deglycosylation involved in glycoprotein catabolic process GO:0036503 ERAD pathway GO:0036507 protein demannosylation GO:0036508 protein alpha-1,2-demannosylation GO:0036509 trimming of terminal mannose on B branch GO:0042176 regulation of protein catabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043413 macromolecule glycosylation GO:0044723 single-organism carbohydrate metabolic process GO:0045732 positive regulation of protein catabolic process GO:0051222 positive regulation of protein transport GO:0070085 glycosylation GO:0070861 regulation of protein exit from endoplasmic reticulum GO:0070863 positive regulation of protein exit from endoplasmic reticulum GO:0090316 positive regulation of intracellular protein transport GO:0097466 glycoprotein ERAD pathway GO:1901136 carbohydrate derivative catabolic process GO:1903513 endoplasmic reticulum to cytosol transport GO:1903829 positive regulation of cellular protein localization GO:1904152 regulation of retrograde protein transport, ER to cytosol GO:1904154 positive regulation of retrograde protein transport, ER to cytosol GO:1904292 regulation of ERAD pathway GO:1904294 positive regulation of ERAD pathway GO:1904380 endoplasmic reticulum mannose trimming GO:1904382 mannose trimming involved in glycoprotein ERAD pathway GO:1904587 response to glycoprotein GO:1904951 positive regulation of establishment of protein localization |
Molecular Function |
GO:0001948 glycoprotein binding GO:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds GO:0004559 alpha-mannosidase activity GO:0004571 mannosyl-oligosaccharide 1,2-alpha-mannosidase activity GO:0015923 mannosidase activity GO:0015924 mannosyl-oligosaccharide mannosidase activity GO:0016798 hydrolase activity, acting on glycosyl bonds |
Cellular Component |
GO:0005788 endoplasmic reticulum lumen GO:0044322 endoplasmic reticulum quality control compartment |
KEGG |
hsa04141 Protein processing in endoplasmic reticulum |
Reactome |
R-HSA-446203: Asparagine N-linked glycosylation R-HSA-901042: Calnexin/calreticulin cycle R-HSA-901032: ER Quality Control Compartment (ERQC) R-HSA-392499: Metabolism of proteins R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle R-HSA-597592: Post-translational protein modification |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between EDEM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of EDEM2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of EDEM2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of EDEM2 in various data sets.
|
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EDEM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EDEM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EDEM2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EDEM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of EDEM2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between EDEM2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | EDEM2 |
Name | ER degradation enhancer, mannosidase alpha-like 2 |
Aliases | FLJ10783; bA4204.1; C20orf49; C20orf31; chromosome 20 open reading frame 31; ER degradation-enhancing alpha- ...... |
Chromosomal Location | 20q11.22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting EDEM2 collected from DrugBank database. |
There is no record. |